Natalie Kelk

Title: Natalie Kelk and Her Pharmaceutical Patent

Introduction

Natalie Kelk is an inventor associated with Midlothian, Great Britain. Her patent work concerns pharmaceutical compounds investigated for their potential relevance to cancer and other diseases.

Latest Patents

The supplied information identifies one patent associated with Kelk: “Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine.” The invention covers salts and polymorphic forms of Compound A, a compound described as an inhibitor of Aurora kinase and FMS-like tyrosine kinase 3 (FLT3) activity. It also addresses methods for preparing these forms, pharmaceutical compositions containing them, and their potential use in treating proliferative disorders, including cancer, and other conditions in which Aurora kinase or FLT3 activity is implicated. The supplied record lists 1 patent.

Career Highlights

Kelk is associated with Ellipses Pharma Limited and the Institute of Cancer Research: Royal Cancer Hospital. The patent’s focus on compound forms, preparation processes, and pharmaceutical applications reflects work in drug development and cancer-related research.

Collaborations

The supplied information names Jonathan Loughrey and Michaela Kreiner as Kelk’s coworkers. Their inclusion indicates professional connections associated with the patent or related work, though specific contributions are not provided.

Conclusion

Natalie Kelk’s listed patent concerns pharmaceutical forms of a kinase-inhibiting compound and their potential therapeutic applications, connecting her recorded work with cancer research and drug development.